Market Place
Sourcing Support
US FDA grants approval for Radius’ Tymlos for osteoporosis in men
22 Dec 2022 //
PHARMACEUTICAL-TECHNOLOGY
Teijin Pharma Receives Approval Japan for Abaloparatide Acetate for Osteoporosis
05 Sep 2022 //
PRESS RELEASE
Radius Health Update on Abaloparatide Transdermal System
01 Jun 2022 //
GLOBENEWSWIRE
Radius Announces Update on TYMLOS® (abaloparatide) Label
23 Dec 2021 //
GLOBENEWSWIRE
Radius Announces Update on TYMLOS® (abaloparatide) Label
23 Dec 2021 //
GLOBENEWSWIRE
Radius Announces Positive Phase 3 Topline Results for TYMLOS®
18 Oct 2021 //
GLOBENEWSWIRE
Endo Announces Licensing Agreement for Paladin Labs to Abaloparatide
05 Jan 2021 //
PRNEWSWIRE
Radius Health: Enrollment Completed for Phase 3 wearABLe trial
08 Sep 2020 //
PRESS RELEASE
Pivotal Phase III trial of abaloparatide-SC in Japanese women and men
26 May 2020 //
GLOBENEWSWIRE
EMA’s CHMP Rejects Another Drug Approved by US FDA
01 Jul 2019 //
RAPS
Amgen sets $21,900 annual price for new Evenity bone drug
17 Apr 2019 //
ENDPTS
Radius International`s Eladynos abaloparatide Rejected by EMA
15 Feb 2019 //
EMA
Six medicines recommended for approval, including one orphan
24 Mar 2018 //
EMA
EMA’s CHMP Rejects Two Drugs Approved by US FDA in 2017
24 Mar 2018 //
RAPS
Fast Start for FDA Drug Approvals in 2017
13 Apr 2017 //
RAPS
Radius CEO Says Drug Application Delayed for `Work-Life Balance`
18 Nov 2015 //
BLOOMBERG
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.